8-K: ACELYRIN and Alumis Amend Merger Agreement, Increasing ACELYRIN Stockholder Ownership

ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis.

Summary

• ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company.
• Under the amended terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock.
• Alumis stockholders will own approximately 52% and ACELYRIN stockholders will own approximately 48% of the combined company on a fully diluted basis.
• The companies expect the transaction to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The special meeting of stockholders for both companies is scheduled for May 13, 2025.
• The combined company is expected to have approximately $737 million in pro forma cash as of December 31, 2024, providing runway into 2027.
• The ACELYRIN Board believes the merger maximizes value for ACELYRIN stockholders and that Alumis is the right partner to optimize development of lonigutamab.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the increased ownership for ACELYRIN stockholders and the potential for value creation. However, it also acknowledges the inherent risks and uncertainties associated with the transaction, leading to a moderately positive sentiment score.

Positives

• ACELYRIN stockholders will receive increased ownership in the combined company.
• The merger is expected to create a stronger combined company with a diversified portfolio of product candidates.
• The combined company is expected to have sufficient cash to fund operations into 2027.
• The ACELYRIN Board believes the merger maximizes value for ACELYRIN stockholders and that Alumis is the right partner to optimize development of lonigutamab.

Negatives

• The merger involves risks and uncertainties, including the potential failure to receive required approvals or to complete the transaction in a timely manner.
• The announcement, pendency, or completion of the merger could affect Alumis' or ACELYRIN's ability to attract and retain key personnel and maintain relationships with partners.
• The integration of the two companies may not occur as anticipated, and the combined company may not be able to achieve the expected growth prospects.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• There is potential failure to receive required approvals, including stockholder approvals.
• The announcement, pendency, or completion of the proposed transaction may affect the ability to attract, motivate, retain, and hire key personnel.
• The proposed transaction may divert management's attention from ongoing business operations.
• There is a risk of legal proceedings related to the proposed transaction.
• Alumis or ACELYRIN may be adversely affected by economic, business, and/or competitive factors.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials exist.

Future Outlook

The combined company expects to advance its pipeline through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, stated that the revised terms enable enhanced value creation opportunities for stockholders and provide Alumis the best opportunity to enhance financial flexibility and advance an expanded late-stage pipeline.
• Bruce Cozadd, Chair of the ACELYRIN Board of Directors, said that the amended agreement reflects dialogue with stockholders and meaningfully builds upon the previously announced agreement, providing stockholders with a greater interest in Alumis' long-term upside potential.

Industry Context

The merger aims to create a leading clinical-stage immunology company with a diversified portfolio of product candidates, positioning it competitively within the biopharmaceutical industry.

Comparison to Industry Standards

• The document compares ACELYRIN's situation to other biotech companies trading below cash value, such as Pliant, BBC, and others.
• It also references Viridian, a company with a derisked anti-IGF-1R for TED, as a trading comparable.
• The document mentions Cosentyx ($4.8B FY22) and Lillys Taltz ($2.5B FY22) as competitors in the Axial Spondyloarthritis space.
• The document references TEPEZZA, a medicine for Thyroid Eye Disease, and the experience of Alumis' Chief Commercial Officer in running the TEPEZZA franchise at Amgen/Horizon.

Stakeholder Impact

• ACELYRIN stockholders will receive increased ownership in the combined company, potentially benefiting from the long-term upside of the combined entity.
• Alumis stockholders will own a majority stake in the combined company, gaining access to ACELYRIN's assets and expertise.
• Employees of both companies may experience changes in roles and responsibilities as the companies integrate.
• Patients may benefit from the development of new therapies and treatments resulting from the combined company's research and development efforts.

Next Steps

• Alumis and ACELYRIN intend to file supplemental proxy materials with the SEC.
• The companies will hold their respective Special Meetings of Stockholders on May 13, 2025.
• The companies expect to close the transaction during the second quarter of 2025, subject to stockholder approval and customary closing conditions.
• Finalize clinical development plan for Lonigutamab in mid-2025.
• Phase 2 clinical trial initiation for A-005 in Multiple Sclerosis in 2H 2025.
• Topline data from Phase 3 ONWARD trials for ESK-001 in Moderate-to-Severe Plaque Psoriasis expected to readout in 1Q 2026.
• Topline data from Phase 2b LUMUS trial for ESK-001 in Systemic Lupus Erythematosus on track for readout in 2026.
• A-005 MS Phase 2 Topline Data in 2026.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, ownership, lonigutamab, ESK-001, immunology, clinical trials, pipeline